<DOC>
	<DOCNO>NCT01844661</DOCNO>
	<brief_summary>The investigator evaluate safety weekly infusion ( n=6 ) CELYVIR child adult metastatic refractory solid tumor . CELYVIR consist bone marrow-derived autologous mesenchymal stem cell ( MSCs ) infect ICOVIR5 , oncolytic adenovirus . In addition data toxicity investigator evaluate clinical response .</brief_summary>
	<brief_title>Safety Efficacy Repeated Infusion CELYVIR Children Adults With Metastatic Refractory Tumors .</brief_title>
	<detailed_description />
	<criteria>Children : Up 18 yr . Refractory least 2 previous therapy line . Life expectancy 6 month . Measurable disease . Adults : 1875 yr . Refractory least 2 previous therapy line . ECOG ( Eastern Cooperative Oncology Group ) &lt; 2 . Measurable disease . Pregnancy . Central Nervous System metastasis . Experimental therapy previous month . Chemotherapy le 3 week previous . Any organ functionally impaired . Concurrent infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Oncolytic adenovirus</keyword>
</DOC>